The pharmaceutical excipients manufacturer Sudeep Pharma Ltd has concluded its highly successful initial public offering, with investors now eagerly awaiting the final allotment decision. The company's IPO, which opened on November 21 and closed on November 25, witnessed overwhelming response from investors across categories.
Sudeep Pharma IPO Allotment Timeline
The much-anticipated Sudeep Pharma IPO allotment is expected to be finalized today, November 26, 2025. This crucial step will determine which applicants receive shares in the company. Following the allotment process, the company plans to credit shares to successful applicants' demat accounts on November 27, while initiating refunds for unsuccessful bidders on the same day.
The final listing of Sudeep Pharma shares is scheduled for November 28 on both Bombay Stock Exchange (BSE) and National Stock Exchange (NSE). This marks a significant milestone for the pharmaceutical excipients manufacturer that has captured market attention.
How to Check Sudeep Pharma IPO Allotment Status
Investors who applied for the IPO can check their allotment status through multiple platforms. The process is straightforward and can be completed online through the following methods:
Checking via BSE Website
Visit the BSE website and navigate to the investor section. Select 'Equity' as the issue type and choose 'Sudeep Pharma Limited' from the dropdown menu. Enter your application number or PAN details, complete the verification process, and your allotment status will be displayed immediately.
Checking via NSE Portal
Alternatively, investors can check through NSE's official website by accessing the IPO bids verification section. Choose 'Equity and SME IPO bids,' select Sudeep Pharma Limited from the issue list, enter your PAN and application number, and submit to view your status.
Checking through Registrar Portal
MUFG Intime India, the official registrar for the Sudeep Pharma IPO, also provides an online platform for status checks. Visit their website, select Sudeep Pharma Limited from the company dropdown, and enter your details using PAN, application number, DP ID, or account number.
Strong Market Response and Financial Details
The Sudeep Pharma IPO demonstrated exceptional market demand with total subscription reaching 93.72 times. The breakdown reveals even more impressive figures: Qualified Institutional Buyers (QIBs) subscribed 213.08 times, Non-Institutional Investors (NIIs) booked 116.72 times, while Retail Individual Investors (RIIs) showed healthy interest with 15.65 times subscription.
The company raised ₹895 crore through this public issue, comprising a fresh issue of 16.02 lakh shares worth ₹95 crore and an offer-for-sale (OFS) component of 1.35 crore shares amounting to ₹800 crore. The price band was set between ₹563 to ₹593 per share.
Grey Market Premium Signals Positive Listing
Current grey market premium (GMP) for Sudeep Pharma shares stands at ₹87 per share, indicating strong secondary market demand. This suggests that the estimated listing price could reach approximately ₹680 per share, representing a nearly 15% premium over the upper end of the IPO price band at ₹593.
The robust GMP and overwhelming subscription response reflect investor confidence in Sudeep Pharma's business model and growth prospects in the pharmaceutical excipients manufacturing sector.
ICICI Securities served as the book running lead manager for this public issue, with MUFG Intime India handling registrar responsibilities. Investors should monitor their demat accounts and email communications for updates regarding share allotment and refund processes.
